Saturday, April 20, 2024
HomeFunding Boston-based Apollo Therapeutics Secures USD 33.5M in a Second Close of...

[Funding alert] Boston-based Apollo Therapeutics Secures USD 33.5M in a Second Close of its Series C Round Funding

Boston-based Apollo Therapeutics raises USD 33.5 million in funding at the Series C round's second close. The $260 million round, led by Patient Square Capital, brought together a number of new investors, including M&G plc and two of the largest US public pension plans, along with some old ones, like Rock Springs Capital.

Boston-based Apollo Therapeutics raises USD 33.5 million in funding at the Series C round’s second close. The $260 million round, led by Patient Square Capital, brought together a number of new investors, including M&G plc and two of the largest US public pension plans, along with some old ones, like Rock Springs Capital.

The company intends to use the funds to further fund its drug discovery and development activities based on advancements in basic medical research made at its partner institutions, licence or buy more clinical stage programmes that meet strict selection criteria, and advance pipeline programmes through clinical development.

Read also – CA-based Hyperlink Ventures Secures it’s First fund at $32M

The CEO of Apollo Therapeutics, a portfolio biopharmaceutical company, is Dr. Richard Mason. The company’s goal is to commercialise basic medical research into drugs.

The core of the portfolio model is a centralised management team comprising capital allocators and functional leaders with deep expertise in pharmaceutical R&D, manufacturing, commercial strategy, fund-raising, and business development. After that, this group is used for a variety of therapeutic initiatives, all of which are managed by seasoned and devoted asset leaders.

Read also – ME-based Biochar Producer Standard Biocarbon Secures $5M in Funding

About Apollo Therapeutics

Apollo Therapeutics, As a portfolio biotech, they work on a variety of medication programmes to generate value for our investors, patients, and inventors. Their objective is to build a varied clinical-stage asset portfolio with a focus on high-value markets. They offer over 20 programmes in their three primary biological focus areas: cell signalling, cell stress response, and immunology.

Read also – CA-based Hyperlink Ventures Secures it’s First fund at $32M

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular